StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb Co. (BMY) PT Raised to $65 at Goldman Sachs, Positively Revises EPS Estimates
September 7, 2017 9:53 AM
Goldman Sachs raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Bristol-Myers Squibb (BMY) Reports Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) in Phase 3 CheckMate -238 Study
September 11, 2017 6:21 AM
Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 Trial
September 11, 2017 6:16 AM
Bristol-Myers Squibb (BMY) Reports Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
September 8, 2017 5:49 AM
